Several studies indeed showed that MAPK signaling rebound in glioma can be overcome by adding MEK inhibition, including our work with a BRAFV600E murine glioma cell line (2341) which were derived from an adenovirus-induced tumor in a Cre-inducible mouse model in which BRAFV600E is expressed under the endogenous promoter, and hence under physiologic levels (22) (Figure 1). This evidence concerns the gene MAP2K7 and glioma.